Health care - Associated infection prevention and control: Pharmacists' role in meeting national patient safety goal 7

Hospital Pharmacy

Volumn 44, Issue 5, 2009, Pages 401-411

  Tauman, Allison V ^f   Robicsek, Ari ^a,b   Roberson, Joyce ^c   Boyce, John M ^d,e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c Mobile Infirmary Medical Center   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL OF SAINT RAPHAEL   (United States)

^f VHA Performance Services   (United States)

Author keywords

Antimicrobial stewardship program; CLA BSI; HAIs; Health care associated infections; Infection prevention; MRSA; National patient safety goals; NPSG 7

Indexed keywords

CHLORHEXIDINE; FLUCONAZOLE; LINEZOLID; PSEUDOMONIC ACID;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COMMUNITY HOSPITAL; COST BENEFIT ANALYSIS; DRUG USE; HEALTH CARE QUALITY; HOSPITAL INFECTION; HOSPITAL MANAGEMENT; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFORMATION TECHNOLOGY; LENGTH OF STAY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PATIENT MONITORING; PATIENT SAFETY; PHARMACIST; REVIEW; UNITED STATES;

EID: 68249146343     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4405-401     Document Type: Review

References (45)

1. Centers for Disease Control and Prevention. Infection control in healthcare settings. http://www.cdc.gov:80/ncidod /dhqp. Accessed February 17, 2009.
2. Centers for Medicare & Medicaid Services. Hospital-acquired conditions. http://www.cms.hhs.gov/HospitalAcq Cond/06-Hospital-Acquired-Condi tions.asp#TopOfPage. Updated February 19, 2009. Accessed February 17, 2009.
3. The Joint Commission. 2009 national patient safety goals: ambulatory care program. http://www.jointcommission .org/PatientSafety/NationalPatientSafe tyGoals/09-amb-npsgs.htm. Accessed February 17, 2009.
4. Blaser M. Infectious Diseases Society of America to Senator Hatch [letter]. http://www.idsociety.org/WorkArea/down loadasset.aspx?id=3020. Published October 24, 2005. Accessed March 4, 2009.
5. Owens RC Jr, Rice L. Hospital-based strategies for combating resistance. Clin Infect Dis. 2006;42(suppl 4):S173-S181.
6. Thuong M, Shortgen F, Zazempa V, Girou E, Soussy CJ, Brun-Buisson C. Appropriate use of restricted antimicrobial agents in hospitals: the importance of empirical therapy and assisted re-evaluation. J Antimicrob Chemother. 2000;46(3):501-508.
7. Cited by: Erbay A, Colpan A, Bodur H, Cevik MA, Samore MH, Ergönül O. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Int J Antimicrob Agents. 2003;21(4):308-312.
8. Tünger O, Dinç G, Ozbakkaloglu B, Atman UC, Algün U. Evaluation of rational antibiotic use. Int J Antimicrob Agents. 2000;15(2):131-135.
9. Cited by: Erbay A, Colpan A, Bodur H, Cevik MA, Samore MH, Ergönül O. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Inter J Antimicrob Agents. 2003;21(4):308-312.
10. Maki DG, Schuna AA. A study of antimicrobial misuse in a university hospital. Am J Med Sci. 1978;275(3):271-282.
11. Cited by: Erbay A, Colpan A, Bodur H, Cevik MA, Samore MH, Ergönül O. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Inter J Antimicrob Agents. 2003;21(4):308-312.
12. Dunagan WC, Woodward RS, Medoff G, et al. Antibiotic misuse in two clinical situations: positive blood culture and administration of aminoglycosides. Rev Infect Dis. 1991;13(3):405-412.
13. Cited by: Erbay A, Colpan A, Bodur H, Cevik MA, Samore MH, Ergönül O. Evaluation of antibiotic use in a hospital with an antibiotic restriction policy. Inter J Antimicrob Agents. 2003;21(4):308-312.
14. Dellit TH, Owens RC, McGowan JE Jr, et al; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2): 159-177.
15. McQuillen DP, Petrak RM, Wasserman RB, Nahass RG, Scull JA, Martinelli LP. The value of infectious diseases specialists: non-patient care activities. Clin Infect Dis. 2008;47(8):1051-1063.
16. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheterrelated bloodstream infections in the intensive care unit. Crit Care Med. 2004;32(10):2014-2020. (Pubitemid 39372534)
17. Centers for Medicare & Medicaid Services (CMS), HHS. Medicare program; changes to the hospital inpatient prospective payment systems and fiscal year 2008 rates. Fed Regist. 2007; 72(162):47129-48175.
18. Data on file, Mobile Infirmary Medical Center, Mobile, Alabama.
19. The Joint Commission. Facts about the national patient safety goals. http: //www.jointcommission.org/PatientSafe ty/NationalPatientSafetyGoals/npsg- facts .htm. Updated December 2008. Accessed February 17, 2009.
20. Robicsek A, Beaumont JL, Paule S, et al. Universal surveillance for methicillinresistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med. 2008;148(6):409-418. (Pubitemid 351665440)
21. Huang SS, Yokoe DS, Hinrichsen VL, et al. Impact of routine intensive care unit surveillance cultures and resultant barrier precautions on hospital-wide methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2006; 43(8):971-978.
22. Harbarth S, Masuet-Aumatell C, Schrenzel J, et al. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit Care. 2006;10(1):R25. (Pubitemid 47079796)
23. Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillinresistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA. 2008;299 (10):1149-1157.
24. Keshtgar MR, Khalili A, Coen PG, et al. Impact of rapid molecular screening for methicillin-resistant Staphylococcus aureus in surgical wards. Br J Surg. 2008;95(3):381-386.
25. Robicsek A, Suseno M, Beaumont JL, Thomson RB Jr, Peterson LR. Prediction of methicillin-resistant Staphylococcus aureus involvement in disease sites by concomitant nasal sampling. J Clin Microbiol. 2008;46(2):588-592. (Pubitemid 351231306)
26. Robicsek A, Beaumont JL, Thomson RB, et al. Topical therapy for methicillinresistant Staphylococcus aureus colonization: impact on infection risk. Infect Cont Hosp Epidemiol. In press.
27. Perl TM, Cullen J, Wenzel R, et al; Mupirocin and the Risk of Staphylococcus Aureus Study Team. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med. 2002;346(24):1871-1877.
28. Wertheim HF, Vos MC, Ott A, et al. Mupirocin prophylaxis against nosocomial Staphylococcus aureus infections in nonsurgical patients: a randomized study. Ann Intern Med. 2004; 140(6): 419-425. (Pubitemid 38327329)
29. Paule SM, Robicsek A, Thomson R, et al. Three years of universal surveillance and decolonization: the effect on mupirocin resistance. Paper presented at: Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC.
30. Tacconelli E, Cataldo MA, Albanese A, et al. Vancomycin versus cefazolin prophylaxis for cerebrospinal shunt placement in a hospital with a high prevalence of methicillin-resistant Staphy lococcus aureus. J Hosp Infect. 2008; 69(4):337-344.
31. Finkelstein R, Rabino G, Mashiah T, et al. Vancomycin versus cefazolin prophylaxis for cardiac surgery in the setting of a high prevalence of methicillinresistant staphylococcal infections. J Thorac Cardiovasc Surg. 2002;123(2): 326-332. (Pubitemid 34127121)
32. Bratzler DW, Houck PM for the Surgical Infection Prevention Guidelines Writers Workgroup. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis. 2004;38(12):1706-1715.
33. LeBlanc L, Pépin J, Toulouse K, et al. Fluoroquinolones and risk for methicillin- resistant Staphylococcus aureus, Canada. Emerg Infect Dis. 2006;12(9): 1398-1405. (Pubitemid 44455216)
34. Baggett HC, Hennessy TW, Rudolph K, et al. Community-onset methicillinresistant Staphylococcus aureus associated with antibiotic use and the cytotoxin Panton-Valentine leukocidin during a furunculosis outbreak in rural Alaska. J Infect Dis. 2004;189:1565-1573. (Pubitemid 38648283)
35. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobialassociated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(suppl 1):S19-S31. (Pubitemid 351323662)
36. Pépin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254-1260. (Pubitemid 41532667)
37. Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect. 2005;11(suppl 5):4-16.
38. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003; 24(9):699-706. (Pubitemid 37221343)
39. Valiquette L, Cossette B, Garant MP, Diab H, Pépin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007;45(suppl 2):S112-S121. (Pubitemid 47328625)
40. Owens RC Jr. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn Microbiol Infect Dis. 2008;61(1):110-128.
41. Ramirez JA, Vargas S, Ritter, G et al. Early switch from intravenous to oral antibiotics and early hospital discharge. Arch Int Med. 1999;159(20):2449-2454.
42. World Health Organization Collaborating Centre for Drug Statistics Methodology. http://www.whocc.no/atc ddd. Accessed February 17, 2009.
43. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8): 470-485.
44. Zagorski BM, Trick WE, Schwartz DN, et al. The effects of renal dysfunction on antimicrobial use measurements. Clin Inf Dis. 2002;35(12):1491-1497. (Pubitemid 36020692)
45. Data on file, Cardinal Health Pharmacy Services, Houston, TX.